Endocrine Sensitive HER2+/HR+ Breast Cancer Clinical Trial
Official title:
PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study
The purpose of this study is to evaluate the activity of molecular response in endocrine sensitive breast cancer HER2+/HR+ patients treated with Pertuzumab-trastuzumab plus Ietrozole.
The purpose of this study is:
- to evaluate the rate of pathologic complete response (pCR), as defined as complete
disappearance of invasive tumor in breast and axillary nodes.
- to estimate the percentage of clinical objective responses (cOR) (complete plus partial)
in the breast, as assessed by ultrasonography (US)
- to estimate the percentage of breast conservative surgery
- to evaluate the safety profile
- To perform correlative biomarker analyses
;